96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01632462 (ClinicalTrials.gov)	September 2012	25/6/2012	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	Crohn's Disease	Drug: VSL#3	Federico II University	NULL	Recruiting	5 Years	17 Years	Both	30	Phase 4	Italy
2	NCT01548014 (ClinicalTrials.gov)	January 2010	17/2/2012	The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease	Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study	Crohn's Disease	Dietary Supplement: VSL#3	Samsung Medical Center	NULL	Recruiting	13 Years	17 Years	Both	1	Phase 3	Korea, Republic of
3	NCT00367705 (ClinicalTrials.gov)	August 2009	22/8/2006	VSL#3 Treatment in Children With Crohn's Disease	Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease	Crohn's Disease	Dietary Supplement: VSL#3®;Dietary Supplement: Placebo	Hadassah Medical Organization	NULL	Not yet recruiting	6 Years	18 Years	Both	300	Phase 4	Israel
4	NCT00944736 (ClinicalTrials.gov)	July 2009	22/7/2009	Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease	Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission	Crohn's Disease	Dietary Supplement: VSL#3;Dietary Supplement: Placebo	Children's Mercy Hospital Kansas City	VSL Pharmaceuticals	Completed	11 Years	17 Years	Both	12	Phase 3	United States
5	NCT00114465 (ClinicalTrials.gov)	June 2005	14/6/2005	VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease	Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease	Crohn's Disease	Drug: VSL#3;Other: Placebo	Orphan Australia	NULL	Completed	18 Years	75 Years	Both	38	Phase 4	Australia
6	NCT00175292 (ClinicalTrials.gov)	December 2003	13/9/2005	A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.	A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.	Crohn's Disease;Inflammatory Bowel Disease	Drug: Probiotic - VSL#3	University of Alberta	Canadian Institutes of Health Research (CIHR)	Completed	16 Years	N/A	Both	120	Phase 3	Canada